Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Biomedical Reports|February 15, 2021
Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux diseaseSatoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, et al.
The Journal of Medical Investigation : JMI|September 21, 2016
The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsiaSatoshi Shinozaki, Hiroyuki Osawa, Hirotsugu Sakamoto, et al.
World Journal of Gastrointestinal Endoscopy|August 23, 2012
Diagnosis of extent of early gastric cancer using flexible spectral imaging color enhancementHiroyuki Osawa, Hironori Yamamoto, Yoshimasa Miura, et al.
Free Radical Research|December 29, 2004
Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and non-pregnancyOsamu Ishihara, Masatoshi Hayashi, Hiroyuki Osawa, et al.
Journal of Gastroenterology|March 2, 2002
Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasiaAkashi Eda, Hiroyuki Osawa, Ichiro Yanaka, et al.
Helicobacter|May 10, 2008
Assessment of atrophic gastritis using the OLGA systemKiichi Satoh, Hiroyuki Osawa, Mitsuyo Yoshizawa, et al.
Digestion|September 22, 2021
Long-Term Outcomes in Patients with Post-Bulbar Ulcer Bleeding Compared to Bulbar Ulcer Bleeding in the DuodenumHiromi Sekiguchi, Satoshi Shinozaki, Takahito Takezawa, et al.
Scandinavian Journal of Gastroenterology|September 21, 2021
Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Helicobactor pylori eradication therapySatoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, et al.
Digestion|January 9, 2020
Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-AnalysisSatoshi Shinozaki, Yasutoshi Kobayashi, Hiroyuki Osawa, et al.
Biomedical Reports|September 13, 2017
Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux diseaseSatoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, et al.
Pageof 9